FROM THE EDITORS
Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.
For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.
 |
 |
|
Katie Newlin, RN, MSN, AGPCNP-BC Washington University in St. Louis/Siteman Cancer Center
|
Lisa Salem, MSN, FNP-BC, AOCNP Washington University in St. Louis/Siteman Cancer Center |
Resources
Oral Chemotherapy Education
Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer
Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer
News & Literature Highlights